NoGeneST™ Anti-LRRK2 Aptamer, aLRRK2 aptamer

Name: NoGeneST™ Anti-LRRK2 Aptamer, aLRRK2 aptamer
SKU: NRYF-0625-HZ89
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ89]

Aptamer designed to specifically recognize Leucine-Rich Repeat Kinase 2, a key protein kinase implicated in Parkinson's disease.

Target:: LRRK2

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Relevant Diseases

Parkinson's Disease

Properties

Size

5 nmol. 10 nmol. 50 nmol

Soluble In

PBS; buffer system with Serum; other

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

LRRK2

Full Name

Leucine-Rich Repeat Kinase 2

Alternative Names

PARK8; Dardarin

Gene ID

120892

Uniprot ID

Q5S007

Target Overview

Leucine-rich repeat kinase 2 (LRRK2) is a large, multi-domain enzyme that has both kinase and GTPase enzymatic functions. While its precise physiological roles are still being fully elucidated, LRRK2 is best known for its strong genetic association with Parkinson's disease. Mutations in the LRRK2 gene are the most frequent cause of both familial (inherited) and sporadic Parkinson's disease. These pathogenic mutations typically lead to a toxic gain-of-function by increasing the protein's kinase activity, which is thought to contribute to neuronal damage. This makes LRRK2 a primary therapeutic target for the development of kinase inhibitors.

Publications